MeSH term
Frequency | Condition_Probility | Adult | 33 | 0.0 |
Age of Onset | 4 | 0.0 |
Alzheimer Disease/*genetics | 18 | 5.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Humans | 229 | 0.0 |
Male | 54 | 0.0 |
Membrane Proteins/*genetics | 12 | 1.0 |
*Mutation | 6 | 0.0 |
Pedigree | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 155 | 0.0 |
Alzheimer Disease/*metabolism | 17 | 8.0 |
Amyloid beta-Protein Precursor/*metabolism | 20 | 29.0 |
Blotting, Northern | 5 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Cells, Cultured | 18 | 0.0 |
Immunohistochemistry | 20 | 0.0 |
Plasmids/metabolism | 5 | 0.0 |
RNA/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Time Factors | 10 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Transfection | 24 | 0.0 |
Binding Sites | 13 | 0.0 |
Endopeptidases/*metabolism | 8 | 6.0 |
Kinetics | 23 | 0.0 |
Models, Molecular | 2 | 0.0 |
Recombinant Proteins/antagonists & inhibitors | 2 | 4.0 |
Amyloid beta-Protein/metabolism | 8 | 15.0 |
Animals | 106 | 0.0 |
COS Cells | 2 | 0.0 |
Cell Line | 25 | 0.0 |
Cytoplasm/metabolism | 6 | 0.0 |
Mice | 39 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Protein Binding | 16 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Signal Transduction | 6 | 0.0 |
Tumor Cells, Cultured | 11 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Amino Acid Sequence | 29 | 0.0 |
Comparative Study | 31 | 0.0 |
Female | 51 | 0.0 |
Membrane Proteins/genetics/*metabolism | 3 | 1.0 |
Nerve Tissue Proteins/genetics/*metabolism | 4 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 80 | 0.0 |
Aged | 47 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/*adverse effects | 2 | 4.0 |
Middle Aged | 43 | 0.0 |
Amyloid beta-Protein/*biosynthesis | 5 | 41.0 |
Nerve Tissue Proteins/*biosynthesis | 3 | 9.0 |
Polymerase Chain Reaction | 9 | 0.0 |
RNA, Messenger/analysis | 7 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Molecular Sequence Data | 41 | 0.0 |
Apolipoproteins E/genetics | 9 | 2.0 |
Chromosome Mapping | 5 | 0.0 |
Genetic Markers | 4 | 0.0 |
Genotype | 8 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Neuropsychological Tests | 3 | 1.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Amyloid beta-Protein Precursor/*chemistry | 3 | 50.0 |
Cytoplasm/chemistry | 2 | 1.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Models, Biological | 7 | 0.0 |
Rats | 24 | 0.0 |
Alzheimer Disease/metabolism | 8 | 12.0 |
Caenorhabditis elegans | 2 | 2.0 |
Drosophila | 2 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Species Specificity | 6 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Aged, 80 and over | 13 | 0.0 |
Multigene Family | 3 | 0.0 |
Amyloid beta-Protein/biosynthesis | 3 | 42.0 |
Amyloid beta-Protein Precursor/genetics | 10 | 20.0 |
Membrane Proteins/genetics | 10 | 2.0 |
Mutation | 19 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Amyloid beta-Protein Precursor/genetics/metabolism | 5 | 35.0 |
Endopeptidases/metabolism | 9 | 6.0 |
Membrane Proteins/*metabolism | 4 | 0.0 |
Alzheimer Disease/*drug therapy/*genetics | 2 | 50.0 |
Age Factors | 3 | 0.0 |
Alzheimer Disease/genetics/*metabolism | 3 | 10.0 |
Amyloid beta-Protein Precursor/*genetics | 19 | 30.0 |
Blood-Brain Barrier/*physiology | 3 | 7.0 |
Disease Models, Animal | 9 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Transgenic | 18 | 0.0 |
Rats, Sprague-Dawley | 6 | 0.0 |
PC12 Cells | 4 | 1.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Amyloid beta-Protein/*metabolism | 3 | 3.0 |
Endopeptidases/*physiology | 2 | 14.0 |
Neurons/metabolism | 5 | 1.0 |
Predictive Value of Tests | 2 | 0.0 |
Amyloid beta-Protein Precursor/chemistry/*metabolism | 3 | 30.0 |
Glycosylation | 4 | 0.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Protein Processing, Post-Translational | 9 | 1.0 |
Apoptosis | 2 | 0.0 |
Inflammation | 2 | 0.0 |
Amyloid beta-Protein Precursor/genetics/*metabolism | 9 | 32.0 |
Gene Expression | 3 | 0.0 |
Half-Life | 2 | 0.0 |
Lysine Carboxypeptidase/metabolism | 2 | 100.0 |
Metalloendopeptidases/blood | 2 | 28.0 |
Blotting, Western | 14 | 0.0 |
Brain Chemistry/genetics | 2 | 4.0 |
Case-Control Studies | 3 | 0.0 |
Cerebral Cortex/*metabolism | 3 | 5.0 |
Gene Expression Regulation | 4 | 0.0 |
In Vitro | 11 | 0.0 |
Nerve Tissue Proteins/*metabolism | 7 | 2.0 |
Apolipoproteins E/*genetics | 5 | 0.0 |
English Abstract | 13 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Acute-Phase Proteins/metabolism | 3 | 4.0 |
Adolescent | 7 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 3 | 0.0 |
Infant | 3 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Amyloid beta-Protein Precursor/isolation & purification/*metabolism | 2 | 100.0 |
Binding, Competitive | 2 | 0.0 |
Brain/metabolism | 6 | 0.0 |
CHO Cells | 7 | 0.0 |
Carrier Proteins/isolation & purification/*metabolism | 2 | 6.0 |
Gene Library | 2 | 0.0 |
Hamsters | 8 | 0.0 |
Neurons/*metabolism | 5 | 1.0 |
Membrane Proteins/genetics/metabolism | 2 | 1.0 |
Mutation/genetics | 5 | 0.0 |
Alzheimer Disease/*metabolism/pathology | 5 | 5.0 |
Amyloid beta-Protein/genetics/*metabolism | 2 | 18.0 |
Cell Death | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Hippocampus/metabolism/pathology | 3 | 10.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Acute-Phase Proteins/*metabolism | 4 | 7.0 |
Prospective Studies | 7 | 0.0 |
Amyloid beta-Protein Precursor/metabolism | 7 | 20.0 |
Point Mutation/genetics | 2 | 0.0 |
Membrane Proteins/*physiology | 2 | 1.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Peptide Fragments/metabolism | 7 | 1.0 |
Amyloid beta-Protein Precursor/*genetics/*metabolism | 2 | 50.0 |
Brain Chemistry/*genetics | 2 | 4.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
*Peptides | 2 | 3.0 |
*Plant Proteins | 2 | 3.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Membrane Proteins/metabolism | 4 | 0.0 |
Phenotype | 3 | 0.0 |
DNA Probes | 3 | 0.0 |
Embryo | 3 | 0.0 |
LDL-Receptor Related Protein 1 | 2 | 1.0 |
Guinea Pigs | 2 | 0.0 |
Membranes, Artificial | 2 | 2.0 |
Reference Values | 5 | 0.0 |
alpha 1-Antitrypsin/biosynthesis | 2 | 25.0 |
Risk Factors | 6 | 0.0 |
Biotinylation | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Amyloid beta-Protein Precursor/*genetics/metabolism | 3 | 60.0 |
Apolipoproteins E/metabolism | 2 | 3.0 |
Nuclear Proteins/*metabolism | 7 | 1.0 |
Microsomes, Liver/*metabolism | 2 | 1.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Temperature | 2 | 0.0 |
Antiplasmin/analysis | 2 | 5.0 |
Antithrombin III/analysis | 2 | 1.0 |
Biological Markers/blood | 2 | 0.0 |
Peptide Hydrolases/analysis | 2 | 1.0 |
Plasmin/analysis | 2 | 4.0 |
Statistics, Nonparametric | 2 | 0.0 |
Acute-Phase Proteins/*biosynthesis | 7 | 31.0 |
Fibrinogen/biosynthesis | 4 | 36.0 |
Haptoglobins/biosynthesis | 2 | 33.0 |
Leucine/metabolism | 2 | 3.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Adenoviridae/genetics | 2 | 0.0 |
Astrocytes/metabolism | 2 | 2.0 |
Cerebral Cortex/metabolism | 2 | 3.0 |
Immunoblotting | 7 | 0.0 |
Drug Design | 3 | 0.0 |
Molecular Structure | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Alternative Splicing | 3 | 0.0 |
Molecular Weight | 9 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Base Sequence | 18 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Phosphorylation | 3 | 0.0 |
Homeostasis | 2 | 0.0 |
Acute-Phase Proteins/*analysis | 5 | 6.0 |
C-Reactive Protein/analysis | 10 | 1.0 |
Interleukin-6/*blood | 3 | 1.0 |
Orosomucoid/analysis | 4 | 8.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Severity of Illness Index | 5 | 0.0 |
Cattle | 6 | 0.0 |
Frontal Lobe/*metabolism | 2 | 22.0 |
Blood Platelets/drug effects/*metabolism | 2 | 2.0 |
Calcium/metabolism | 2 | 0.0 |
Thrombin/pharmacology | 2 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Hela Cells | 6 | 0.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Amyloid beta-Protein Precursor/*chemistry/metabolism | 4 | 80.0 |
Microscopy, Electron | 4 | 0.0 |
Protein Conformation | 4 | 0.0 |
Chromatography, Affinity | 5 | 0.0 |
Fibroblasts | 2 | 0.0 |
Trypsin/metabolism | 2 | 1.0 |
Biological Transport | 2 | 0.0 |
Brain/*metabolism | 5 | 1.0 |
Chromosomes, Human, Pair 21 | 3 | 2.0 |
Brain/metabolism/pathology | 2 | 1.0 |
Genetic Vectors | 3 | 0.0 |
Peptide Fragments/genetics/metabolism | 2 | 1.0 |
Culture Media, Conditioned | 2 | 0.0 |
Neuroblastoma | 2 | 1.0 |
Alzheimer Disease/genetics/metabolism | 3 | 30.0 |
Cell Survival/drug effects | 2 | 0.0 |
Heparin/*metabolism | 3 | 3.0 |
Chromatography, Gel | 2 | 0.0 |
Dimerization | 2 | 0.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Models, Genetic | 2 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 3 | 3.0 |
Cell Line, Tumor | 3 | 0.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Receptors, Interleukin-1/antagonists & inhibitors | 2 | 3.0 |
Solubility | 5 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Acute-Phase Proteins/physiology | 2 | 33.0 |
Cytokines/physiology | 2 | 1.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
DNA Primers | 4 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Blood Sedimentation | 4 | 2.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Restriction Mapping | 4 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Brain Chemistry | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Zinc/*metabolism | 2 | 3.0 |
*Blood Coagulation | 2 | 0.0 |
*Fibrinolysis | 2 | 1.0 |
Acute Disease | 2 | 0.0 |
Amyloid beta-Protein Precursor/biosynthesis/genetics | 2 | 40.0 |
*Chromosomes, Human, Pair 21 | 3 | 1.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Interleukin-6/blood | 3 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Amyloid beta-Protein Precursor/*blood | 2 | 100.0 |
Blood Platelets/*chemistry | 3 | 8.0 |
Ubiquitins/*metabolism | 2 | 1.0 |
Lod Score | 2 | 0.0 |
Molecular Conformation | 3 | 1.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Brain/pathology | 3 | 0.0 |
Autoradiography | 3 | 0.0 |
Histocytochemistry | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Golgi Apparatus/metabolism | 2 | 1.0 |
Organ Specificity | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Exons | 2 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Amyloid beta-Protein Precursor/*biosynthesis | 2 | 33.0 |
Substrate Specificity | 6 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Amyloid beta-Protein Precursor | 11 | 73.0 |
Liver/metabolism | 2 | 0.0 |
Placenta/enzymology | 2 | 2.0 |
Pregnancy | 3 | 0.0 |
Pyridines/*metabolism | 2 | 20.0 |
Amyloid/*genetics | 3 | 8.0 |
*Brain Chemistry | 2 | 1.0 |
*Gene Expression | 2 | 0.0 |
*Protease Inhibitors | 3 | 27.0 |
Protein Precursors/*genetics | 3 | 2.0 |
alpha 1-Antichymotrypsin/*blood | 2 | 22.0 |
DNA Mutational Analysis | 3 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Fibrinogen/analysis | 2 | 1.0 |
alpha 1-Antitrypsin/analysis | 2 | 2.0 |
Brain/*pathology | 2 | 1.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Heterozygote | 2 | 0.0 |
Protease Inhibitors/pharmacology/therapeutic use | 2 | 50.0 |
tau Proteins/genetics | 2 | 28.0 |